CL2009001323A1 - Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc. - Google Patents
Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc.Info
- Publication number
- CL2009001323A1 CL2009001323A1 CL2009001323A CL2009001323A CL2009001323A1 CL 2009001323 A1 CL2009001323 A1 CL 2009001323A1 CL 2009001323 A CL2009001323 A CL 2009001323A CL 2009001323 A CL2009001323 A CL 2009001323A CL 2009001323 A1 CL2009001323 A1 CL 2009001323A1
- Authority
- CL
- Chile
- Prior art keywords
- hplc
- measurement
- sample
- antigen
- obtaining
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
- G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Método que mide estabilidad de antígeno que comprende obtener una primera medición por cromatografía líquida (HPLC) del antígeno en una muestra, obtener una segunda medición por HPLC en una segunda muestra, y cuantificar los cambios de la segunda medición en comparación a la primera por HPLC.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5734608P | 2008-05-30 | 2008-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009001323A1 true CL2009001323A1 (es) | 2009-10-23 |
Family
ID=40905178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009001323A CL2009001323A1 (es) | 2008-05-30 | 2009-05-29 | Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110091984A1 (es) |
EP (1) | EP2285461A1 (es) |
JP (1) | JP2011522252A (es) |
AR (1) | AR071931A1 (es) |
BR (1) | BRPI0913237A2 (es) |
CA (1) | CA2725450A1 (es) |
CL (1) | CL2009001323A1 (es) |
MX (1) | MX2010013148A (es) |
TW (1) | TW201009337A (es) |
WO (1) | WO2009146286A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11435351B2 (en) | 2018-04-18 | 2022-09-06 | Biomadison, Inc. | Methods for determining vaccine potency |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2393298C (en) * | 1999-12-02 | 2011-02-01 | Chiron Corporation | Compositions and methods for stabilizing biological molecules upon lyophilization |
EP1913956A1 (en) | 1999-12-02 | 2008-04-23 | Novartis Vaccines and Diagnostics, Inc. | Compositons and methods for stablizing biological molecules upon lyophilization |
GB0406013D0 (en) * | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
GB0413868D0 (en) * | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
-
2009
- 2009-05-19 TW TW098116556A patent/TW201009337A/zh unknown
- 2009-05-21 MX MX2010013148A patent/MX2010013148A/es not_active Application Discontinuation
- 2009-05-21 CA CA2725450A patent/CA2725450A1/en not_active Abandoned
- 2009-05-21 BR BRPI0913237A patent/BRPI0913237A2/pt not_active IP Right Cessation
- 2009-05-21 EP EP09755648A patent/EP2285461A1/en not_active Withdrawn
- 2009-05-21 JP JP2011511725A patent/JP2011522252A/ja active Pending
- 2009-05-21 WO PCT/US2009/044775 patent/WO2009146286A1/en active Application Filing
- 2009-05-21 US US12/994,251 patent/US20110091984A1/en not_active Abandoned
- 2009-05-28 AR ARP090101902A patent/AR071931A1/es unknown
- 2009-05-29 CL CL2009001323A patent/CL2009001323A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20110091984A1 (en) | 2011-04-21 |
EP2285461A1 (en) | 2011-02-23 |
AR071931A1 (es) | 2010-07-28 |
JP2011522252A (ja) | 2011-07-28 |
WO2009146286A1 (en) | 2009-12-03 |
BRPI0913237A2 (pt) | 2016-01-19 |
CA2725450A1 (en) | 2009-12-03 |
MX2010013148A (es) | 2011-03-21 |
TW201009337A (en) | 2010-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ596659A (en) | Bulbless spectrometer | |
AR053948A1 (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente | |
CR20110567A (es) | Dispositivos para diagnostico y metodos relacionados | |
CO2019012771A2 (es) | Ensayos de diagnóstico para detectar, cuantificar y/o rastrear microbios y otros analitos | |
BR112016007106A2 (pt) | dispositivo e método de teste de gravidez melhorado | |
AR054900A1 (es) | Medidor con alarma de tiempo postprandial para efectuar determinaciones | |
CL2012002741A1 (es) | Metodo para determinar en una muestra de sangre la presencia de vitamina d libre; inmunoensayo para detrminar presencia de vitamina d libre en sangre; kit para efectuar inmunoensayo. | |
CL2008003910A1 (es) | Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida. | |
BR112013010952A2 (pt) | sistemas de rmn e métodos para a detecção rápida de analisados | |
ATE493290T1 (de) | Alcotestgerät | |
ES2570632T3 (es) | Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal | |
DK2155185T3 (da) | Påvisning af succinylacetone | |
ES2674177T3 (es) | Preparación de suero | |
BR112012021590A2 (pt) | detecção de capacitância em ensaio eletroquímico | |
CL2011002973A1 (es) | Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa. | |
BR112016024730A2 (pt) | dispositivo, método e conjunto de análise imunocromatográfica | |
DK2118666T3 (da) | Fremgangsmåde til normalisering af koncentrationen af analytter i en urinprøve | |
ES2684758T3 (es) | Procedimiento para diagnosticar fibrosis hepática | |
BR112014032916A2 (pt) | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco | |
AR059361A1 (es) | Dispositivo y metodos para detectar y cuantificar uno o mas agentes objetivos | |
BR112017027601A2 (pt) | método de tomografia de poço cruzado, sistema para imagear uma formação de subsuperfície e método para obter informações sobre uma formação de subsuperfície | |
EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
AR112996A1 (es) | Métodos de evaluación de conjugados de anticuerpo-fármaco | |
ES2578160T3 (es) | Procedimiento de diagnóstico de infecciones de sitio quirúrgico | |
CL2009001323A1 (es) | Metodo que mide estabilidad de antigeno que comprende obtener una primera medicion por cromatografia liquida (hplc) del antigeno en una muestra, obtener una segunda medicion por hplc en una segunda muestra, y cuantificar los cambios de la segunda medicion en comparacion a la primera por hplc. |